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Objective: Thymic carcinomas are considered to be more aggressive than thymomas and carry a worse progno-
sis. We reviewed our recent experience with the surgical management of thymic tumors and compared the out-
comes and patterns of relapse between patients with thymic carcinoma and those with thymoma.
Methods: We performed a single-institution retrospective cohort study. Data included patient demographics,
stage, treatment, pathologic findings, and postoperative outcomes.
Results:During the period 1995–2006, 120 patients with thymic tumors underwent surgical intervention, includ-
ing 23 patients with thymic carcinoma and 97 patients with thymoma, as classified according to the World Health
Organization 2004 histologic classification. The overall 5-year survival was significantly different between pa-
tients with thymic carcinoma and those with thymoma (thymic carcinoma, 53%; thymoma, 89%; P ¼ .01).
Data on relapse were available for 112 patients. The progression-free 5-year survival was also significantly differ-
ent between patients with thymic carcinoma and those with thymoma (thymic carcinoma, 36%; thymoma, 75%;
P<.01). Using multivariate analysis, thymic carcinoma and incomplete resection were found to be independent
predictors of progression-free survival. Relapses in patients with thymic carcinoma tended to occur earlier, and
occurred significantly more frequently at distant sites than in patients with thymoma (60% vs 13%, P ¼ .01).
Conclusions: Patterns of relapse differ significantly between patients with thymic carcinoma and those with thy-
moma, with lower progression-free survival, earlier onset, and more distant relapses in patients with thymic car-
cinoma. Given the greater propensity for distant failures, the inclusion of systemic therapy in the treatment of
thymic carcinoma might take on greater importance. Despite significantly higher rates of distant relapse, good
overall survival in patients with thymic carcinoma can be achieved.Surgical intervention is considered the mainstay of treatment
for thymic tumors, but despite resection, relapses are com-
mon, and the optimal treatment approaches remain unclear.
Disease progression after treatment tends to occur in the me-
diastinum or the pleural cavity, but some patients return with
distant metastases.1 Given that long-term survival is achiev-
able with resection, freedom from disease progression might
be a more useful metric.2 However, prior studies on recur-
rence can be difficult to compare in the setting of differing
histologic classifications, study periods spanning multiple
decades, inadequate statistical analyses, and a focus on over-
all survival.
A more complete understanding of relapse patterns might
lead to improved strategies for the prevention, surveillance,
and treatment of recurrence. For thymoma, disease stage,
From the Thoracic Service, Department of Surgerya; the Department of Pathologyb;
and the Thoracic Oncology Service, Department of Medicine,c Memorial Sloan–
Kettering Cancer Center, New York, NY.
Read at the Thirty-fourth Annual Meeting of The Western Thoracic Surgical Associ-
ation, Kona, Hawaii, June 25–28, 2008.
Received for publication June 26, 2008; revisions received Feb 23, 2009; accepted for
publication March 23, 2009.
Address for reprints: James Huang, MD, Surgery, Memorial Sloan–Kettering Cancer
Center, 1275 York Ave, Room C-868, New York, NY 10021 (E-mail: huangj@
mskcc.org).
J Thorac Cardiovasc Surg 2009;138:26-31
0022-5223/$36.00
Copyright  2009 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2009.03.03326 The Journal of Thoracic and Cardiovascular Surgas defined by the Masaoka system, and completeness of sur-
gical resection are considered the most consistent predictors
of survival.3,4 Our knowledge of thymic carcinoma (TC) has
been limited because of its rarity, but TC is considered to be
more aggressive and carry a worse prognosis. The number of
conflicting classification systems reflects the persistent con-
fusion surrounding thymic tumors, and even the original
World Health Organization (WHO) classification labeled
TCs as ‘‘Thymoma (Type C).’’5 Although the recent update
of the WHO classification6 officially recognizes the distinc-
tion between TC and thymoma as separate and distinct histo-
logic entities, they tend to be treated fairly similarly. We
hypothesized that the patterns of relapse differ significantly
between patientswith TC and thosewith thymoma, reflecting
different behaviors. We reviewed our recent experience with
the surgical management of thymic tumors to define patterns
and predictors of disease progression.
MATERIALS AND METHODS
We reviewed all patients undergoing resection for thymic epithelial tu-
mors at Memorial Sloan–Kettering Cancer Center between January 1995
and December 2006. The institutional review board granted approval for
this study on August 30, 2005. In this retrospective cohort study we in-
cluded all patients with a pathologic diagnosis of thymoma or TC under
the WHO (2004) histologic classification. All resected specimens were re-
reviewed by one reference pathologist (W.T.) for the purposes of this study
to confirm the diagnosis and the WHO classification. Patients who hadery c July 2009
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PET ¼ positron emission tomography
PFS ¼ progression-free survival
SVC ¼ superior vena cava
TC ¼ thymic carcinoma
WHO ¼ World Health Organization
undergone prior resection, patients with a diagnosis of thymic carcinoid, and
patients presenting with evidence of distant disease (Masaoka stage IVB)
were excluded from this analysis.
Patient characteristics and outcomes were abstracted from medical
records. The independent variables analyzed are listed in Table 1.
Demographic variables included age as continuous and sex and race as cat-
egorical variables. Race categories were defined according to the Surveil-
lance Epidemiology and End Results database definitions.7 Patient
characteristics included pathologic Masaoka stage as a categorical variable,
radiographic tumor size (longest diameter) as a continuous variable, and ad-
ministration of preoperative therapy and postoperative therapy as dichoto-
mous variables. Resection status was determined from the operative notes
and the pathology reports. Resection status was dichotomized as complete
if R0 with microscopically negative margins and incomplete if microscop-
ically or grossly incomplete.
Outcome variables included time from operation to disease progression
and site of progression. Because the proportion of incomplete resections
was high, we used the term disease progression to encompass the occur-
rence of any treatment failure after resection. Disease progression was timed
to the date of the first postoperative radiographic study that demonstrated
progression or recurrence or was censored at the date of the most recent ra-
diographic study documenting absence of disease. Site of progression was
dichotomized as locoregional (confined to the mediastinum or pleural
space) or distant (hematogenous) disease.
Patient characteristics were compared by using 2-tailed t tests for contin-
uous variables, and c2 and Fisher’s exact tests for categorical variables. Re-
lapse was analyzed as a time to event rather than a binary outcome. Survival
was estimated by using the Kaplan–Meier method. Because not all patients
had complete resections, relapse was described in this study in terms of PFS
rather than disease-free survival. Log-rank tests were used for univariate
analysis of survival. Multivariate analysis was conducted by using the
Cox proportional hazards method, incorporating clinically relevant and sig-
nificant variables (P< .10) by means of univariate analysis into the model.
Statistical analyses were conducted with STATA/IC 10.0 software (STAT-
Corp, College Station, Tex).
RESULTS
One hundred twenty patients underwent resection during
the study period and served as the basis for analysis of over-
all survival. Eighteen of these patients formed the basis for
a prior study.8 Of the 120 patients, 3 underwent exploration
only, and 5 were missing data on recurrence status, resulting
in 112 patients for the analysis of disease progression.
Median follow-up was 41 months (mean, 53 months) for
death status and 26 months (mean, 34 months) for disease
progression.
Patient characteristics are summarized in Table 1. The av-
erage age at the time of the operation for all patients in this
study was 58 years, and the ratio of male to female patients
was even overall. White patients (non-Hispanic and His-
panic) formed the predominant category in the distributionThe Journal of Thoracic andof race. In the 111 patients with recorded tumor dimensions,
the average tumor size was 7.1 cm in the longest diameter
(range, 1.2–19 cm). There was no significant difference in
age, sex ratio, race distribution, or tumor size between pa-
tients with TC and those with thymoma (P> .10). With re-
gard to Masaoka stage, there was a significant difference in
the distribution, with patients with TC having an appreciably
greater proportion of higher stages (III and IVA). Overall,
the proportion of complete resection (R0) was 73%, but pa-
tients with TC had a significantly lower proportion of R0 re-
sections compared with those with thymoma (52% vs 76%,
P ¼ .01). Consistent with the higher stage and lower resec-
tion rate, a higher proportion of patients with TC underwent
preoperative therapy (78% vs 43%, P ¼ .003) and postop-
erative therapy (59% vs 38%, P ¼ .06). Identical findings
were obtained when comparing the 112 patients with data
on disease progression, again with only stage, resection
rate, preoperative, and postoperative therapy significantly
different (P< .05).
Preoperative and postoperative therapy regimens are de-
tailed in Table 2. The majority of patients who underwent
preoperative therapy received chemotherapy alone in both
groups. Two patients underwent concurrent chemoradiation
in both groups. All chemotherapy regimens were platinum
based. The most common regimens used in patients with
TC were cisplatin–docetaxel (n ¼ 4), cisplatin–doxorubi-
cin–cyclophosphamide (n ¼ 3), and carboplatin–paclitaxel
TABLE 1. Patient characteristics
Variable
Thymic carcinoma
(n ¼ 23)
Thymoma
(n ¼ 97) P value
Age (y)
Mean 58.1  2.6 58.1  1.5 .99
Sex
Male 15 (65) 46 (47) .13
Female 8 (35) 51 (53)
Race
White 20 (87) 82 (85) .96
Black 1 (4) 5 (5)
Asian 2 (9) 9 (9)
Other 0 (0) 1 (1)
Size* (cm)
Mean 7.0  0.6 7.1  0.4 .94
Stage
I 1 (4) 24 (25) .01
II 5 (22) 32 (33)
III 12 (52) 20 (20)
IVA 5 (22) 21 (22)
Resection
Complete 12 (52) 76 (78) .01
Incomplete 11 (48) 21 (22)
Preoperative therapy 18 (78) 42 (43) .03
Postoperative therapyy 13 (59) 36 (38) .06
Continuous variables are reported as means standard errors. Numbers in parentheses
represent percentages. *n ¼ 17 for thymic carcinoma and n ¼ 94 for thymoma. yn ¼
22 for thymic carcinoma and n ¼ 96 for thymoma.Cardiovascular Surgery c Volume 138, Number 1 27
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with thymoma were cisplatin–etoposide (n¼ 16) and cispla-
tin–doxorubicin–cyclophosphamide (n ¼ 15). Of the pa-
tients who underwent postoperative therapy, the majority
underwent radiation therapy alone in both groups at amedian
dose of 5040 cGy (range, 2500–6600 cGy).
Overall survival was significantly lower at 5 years for pa-
tients with TC (53%) compared with that seen in patients
with thymoma (89%, P ¼ .01). Progression-free survival
(PFS) was significantly different between patients with TC
and those with thymoma (P ¼ .0002). The PFS at 5 years
for patients with TC was 36%, and it was 75% for patients
with thymoma. The median PFS was 29 months for patients
with TC and has not yet been reached for patients with thy-
moma. Univariate analysis of other additional factors predic-
tive of PFS included Masaoka stage (P< .0001), resection
status (P< .0001), preoperative therapy (P< .0001), and
postoperative therapy (P ¼ .01). Age, sex, race, and size
were not found to be significant predictors (P> .10).
Multivariate analysis demonstrated that TC consistently
predicted PFS after adjusting for Masaoka stage, resection
status, and preoperative and postoperative therapy in the
model (Table 3). TC (hazard ratio, 4.1; P ¼ .006) and resec-
tion status (hazard ratio, 22.9; P<.0001) remained the only
significant predictors of PFS in multivariate analysis. Strat-
ifying by these 2 independent predictors, complete resection
resulted in significantly greater PFS in both patients with TC
(P ¼ .0001, 70% vs 0% at 5 years) and patients with thy-
moma (P< .0001, 87% vs 28% at 5 years).
All stage I and II tumors were completely resected (R0).
The extent of disease precluded resection of all gross tumor
in 19 of 58 patients with stage III and IVA disease. The most
TABLE 2. Perioperative therapy
Regimen Thymic carcinoma Thymoma
Preoperative 18 42
Chemotherapy only 16 (89) 40 (95)
Chemoradiotherapy 2 (11) 2 (5)
Postoperative 13 36
Radiotherapy only 8 (62) 26 (72)
Chemotherapy only 0 (0) 5 (14)
Chemoradiotherapy 5 (38) 5 (14)
Numbers in parentheses represent percentages.
TABLE 3. Multivariate analysis of progression-free survival
Variable Hazard Ratio 95% CI P value
Thymic carcinoma 4.1 1.5–11.3 .006
Incomplete Resection 22.9 4.0–133 <.001
Stage
III 1.4 0.2–10.5 .77
IVA 1.0 0.1–8.2 .97
Preoperative therapy 0.5 0.1–3.9 .52
Postoperative therapy 0.5 0.1–1.6 .22
CI, Confidence interval.28 The Journal of Thoracic and Cardiovascular Surgcommon reason for a grossly incomplete resection was inva-
sion of the aorta (n ¼ 7), followed by invasion of the heart
(n ¼ 5), invasion of the superior vena cava (SVC) in con-
junction with other structures (n ¼ 3), unresectable pleural
disease (n ¼ 3), and bilateral diaphragmatic involvement
(n ¼ 1).
Of 112 patients, 25 (22%) were found to have disease
progression. The distribution of sites of progression is
listed in Table 4. Disease progression occurred signifi-
cantly more often at distant sites in patients with TC. In pa-
tients with TC, the majority of relapses (n ¼ 6 [60%])
occurred at distant sites compared with only 2 (13%) in
patients with thymoma (P ¼ .01). The locations of disease
progression are summarized in Table 5. Relapses in pa-
tients with thymoma were overwhelmingly intrathoracic,
with the majority being pleura based. The only distant
site of progression occurred in the lung (distinct from
pleura-based metastases). In patients with TC, distant sites
of progression included the lung, bone, brain, and liver. In
the 25 patients with progression, relapse occurred earlier in
those with TC, with a median time from operation to pro-
gression of 9 in patients with TC and 20 months in patients
with thymoma (Table 6). The time to progression in those
who relapsed was shorter in those who had incomplete re-
sections (8 months) than in those with complete resections
(29 months). Among all patients with progression, the ma-
jority (80%) of incomplete resections led to relapse in less
than 3 years, as did all relapses in patients with TC, regard-
less of resection status.
DISCUSSION
The objective of this study was to characterize and com-
pare the patterns of relapse between patients with TC and
those with thymoma and identify independent predictors
TABLE 4. Comparison of sites of progression
Site
Thymic carcinoma
(n ¼ 10)
Thymoma
(n ¼ 15) P value
Distant 6 (60) 2 (13) .01
Locoregional 4 (40) 13 (87)
TABLE 5. Location of progression
Location Thymic carcinoma (n ¼ 10) Thymoma (n ¼ 15)
Distant
Lung 1 2
Bone 1 –
Bone, lung 1 –
Brain, bone 1 –
lung
Liver 1 –
Liver, lung 1
Locoregional
Pleura 2 8
Mediastinum 2 5ery c July 2009
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exhibit significantly different behavior, with higher stage,
lower resectability, lower overall survival and PFS, more
distant metastases, and earlier relapses. Our data support
the notion that these 2 thymic tumors are clinically distinct
entities with different biologies and add to our understand-
ing of the patterns and natural history of relapse in thymic
tumors. The clinical relevance of this study is strengthened
by a relatively large sample drawn from a recent time period
more reflective of current classifications and treatments.
Consistent with previous reports, overall survival and PFS
were significantly worse in patients with TC in our popula-
tion.3,9-11 Multivariate analysis demonstrated that TC and
incomplete resection, but not stage, were strong independent
predictors of PFS. These results are consistent with reports
that WHO histology is independently predictive of recur-
rence and that Masaoka stage fails to predict outcomes in
TC.10,11 In those reports size was noted to be an important
prognosticator, but we were not able to confirm those find-
ings in our population, possibly because of fewer tumors
that reached their size cutoff (>8 cm).10
The extent of surgical resection is an important consider-
ation given that complete resection is one of the primary deter-
minants of outcome. Incomplete resections occurred only in
Masaoka stage III and IVA thymic tumors. All stage I and II
tumors were completely resected. The extent of disease pre-
cluded resection of all gross tumor in one third of patients
with stage III and IVAdisease,most commonly because of in-
vasion of the aorta or the heart in the majority of cases. Al-
though resection of the SVC was performed when that
would permit a complete resection, the associated morbidity
of an SVC reconstruction in conjunction with extrapleural
pneumonectomy or chest wall resection was deemed unac-
ceptable in 3 cases.Distribution of relapse sites differed signif-
icantly between patients with TC and patients with thymoma,
with diseaseprogressionoccurring at distant sites in themajor-
ity of relapses in patients with TC. These distant sites included
the brain, liver, bone, and lung. The only thymomadistantme-
tastasis occurred in the lung in our series, and others have
noted the lung as the most common site of distant hematoge-
nous metastases as well.12 As with previous observations,
pleural (locoregional) metastases appear to be most common
mode of recurrence in patients with thymoma.10,12-15 Other
extrathoracic sites in patients with thymoma have been re-
TABLE 6. Time to progression in patients with progression
Time to progression (mo)
Type Overall Complete Incomplete
Thymic Carcinoma
(n ¼ 10)
Median 29.4 (4.5–33.4) 22.7 (16.2–29.2) 7.8 (4.5–33.4)
Thymoma (n ¼ 15)
Median 19.5 (3.5–95.0) 45.7 (5.8–64.6) 13.2 (3.5–95.0)The Journal of Thoracic andported in the literature, including 3 patients who had brain
and liver metastases.1,16 The 1 patient with thymoma with
a lungmetastasis originally presented with what is considered
a low-gradehistologic subtype (WHOA), servingasacaution-
ary note that no patient with a thymic tumor is immune from
the potential for distant spread.
Our results should be interpreted in light of several limita-
tions. The analysis of a single-institution experience raises
the issue of external validity. However, this study population
more accurately reflects contemporary management and
might bemore generalizable than prior study populations dat-
ing backmultiple decades. The duration of follow-upwas rel-
atively limited, given the potential for recurrence years after
treatment, but is a direct consequence of selecting amore con-
temporary study population. Nevertheless, significant differ-
ences in PFS were clearly evident early on between tumor
types and resection status. The limited sample population is
a function of the rarity of these tumors, but this study repre-
sents one of the larger experiences with TC in the past de-
cade.17 Although surgical intervention is the mainstay of
treatment, including only patients undergoing surgical man-
agement necessarily injects selection bias and fails to take
into account the outcomes of those who might have been
treated nonsurgically. Although patients were often followed
with annual computed tomographic scans, not all patients had
standardized follow-up, and recurrences might have come to
light only when symptomatic or on serendipitous discovery.
Conversely, patients who died might have had undetected
recurrences. This, along with the average yearlong detection
interval, will tend to overestimate the true time to progres-
sion. However, this is likely more reflective of the day-
to-day reality of medical practice conditions.
Intuitively, relapses would most likely be expected to
occur locally after incomplete resections. Although this
appears to be the case with thymoma, the majority of patients
with TC who had relapses presented with progression at dis-
tant sites, despite the best attempts at curative resection. This
lends support to the idea that TC is a tumor with a more ag-
gressive biology and might behave more like a systemic dis-
ease. The early time course of disease progression raises the
possibility that distant micrometastases might already have
been present at the time of treatment. The significantly
higher frequency of distant failure in patients with TC raises
the question of whether greater consideration should be
given to the inclusion of systemic therapy when the diagno-
sis of TC is established.
The notion that different biologies are at work is reflected
in reports observing differential expression patterns of tyro-
sine kinase receptors in thymic tumors. TCs tend to be c-kit
positive and epidermal growth factor receptor negative,
whereas thymomas tend to be epidermal growth factor re-
ceptor positive and c-kit negative.18-20 The overexpression
of c-kit in TC points to potential new avenues for targeted
therapy, and at least 1 report has documented a clinicalCardiovascular Surgery c Volume 138, Number 1 29
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against c-kit.21
An alternative explanation might be that patients were un-
derstaged at the time of treatment, but with the exception of
brain metastases, most of the other observed sites of distant
relapse in these patients would have been encompassed by
initial chest computed tomographic scans that included the
upper abdomen. Several reports on the utility of positron
emission tomography (PET) in thymoma suggest that this
modality might be helpful in staging and might be particu-
larly appropriate in cases of TC, given the higher potential
for systemic disease.22-24
The high proportion of distant metastases raises further
questions about the value of postoperative radiation in the
treatment of thymic tumors.25-27 Postoperative therapy was
not found to be an independent predictor of progression-
free relapse, although selection bias must be acknowledged,
and all distant relapses occurred in areas outside the radia-
tion field. One hypothesis that has been advanced is whether
concurrent induction chemoradiation might decrease the
likelihood of recurrence.28 By aiming for a pathologic com-
plete response and sterilizing the tumor before surgical inter-
vention, the possibility of shedding viable tumor cells
through surgical manipulation might be lessened. These
questions can only be answered through prospective con-
trolled studies.
Our approach to preoperative biopsy has generally been to
obtain a core biopsy specimen when there was suspicion of
lymphoma or germ cell tumor or when the clinical appear-
ance of a locally invasive thymic tumor raised consideration
for preoperative chemotherapy. Well-circumscribed tumors
typically proceed directly to resection. Distinguishing be-
tween thymoma and TC before resection would likely not
alter the treatment course initially because locally advanced
tumors would be treated with neoadjuvant chemotherapy in
either case in our practice.
Patients with TC that progressed exhibited a tendency to-
ward earlier relapse, as did patients with incomplete resec-
tions. In this series all patients with TC that progressed did
so within the first 3 years, along with 80% of all patients
with progression after R1 or R2 resection. Although it has
been our practice to have annual follow-up, more frequent
surveillance might be appropriate in the first few years in
the setting of TC or incomplete resection. With our latest re-
currence occurring at 95 months, we concur with others in
advocating prolonged, if not lifelong, follow-up.14,29
In conclusion, TC is a distinct entity from thymoma and,
as a more aggressive tumor, has a higher propensity for dis-
tant spread, early relapse, and lower overall survival and
PFS. Our results reiterate the importance of complete resec-
tion and the need for accurate pathologic diagnosis and vig-
ilant surveillance after therapy. The propensity for distant
failure places an emphasis on the need for better systemic
therapies, and prospective efforts to improve our under-30 The Journal of Thoracic and Cardiovascular Surgstanding of the biology and the optimal management of these
tumors is imperative.
We thank Roger Vaughan, PhD, for his statistical expertise in
consultation.
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Discussion
Dr JohnHandy (Portland, Ore). Dr Huang, nice job on the pre-
sentation. I thank the association for allowing me to discuss Memo-
rial Sloan–Kettering’s longstanding work in thymic malignancy,
which dates back to the 1980s.
This is a retrospective report of a large series initiated to remedy
the historical mixing of different histologic classifications, study
periods spanning decades, and analytic end points, should it be dis-
ease-free survival or PFS. Therefore Sloan–Kettering has answered
by using the World Health Organization classification. It is a con-
temporary series, and the end point is PFS. The objective was to
define patterns and predictors of disease progression, and it is admi-
rably accomplished in this data-filled article, the manuscript of
which I received far in advance.
I have 3 questions. The high proportion of both TC and thy-
moma that received induction therapy indicated that the diagnosis
was known preoperatively. What exactly is your preoperative
workup? Do you perform biopsies in all patients? Who is getting
PET scans?
Dr Huang. In general, the patients who are receiving induction
therapy have come to us with a diagnosis from the outside, either
with a needle biopsy or tissue obtained through the Chamberlain
procedure. If the patients come to us presenting with a clinical stage
III or IVA tumor, namely with invasion into the mediastinum or
pleural disease, and they do not have biopsy results, we will pro-
ceed with either interventional radiology for a needle biopsy or
do a Chamberlain procedure, if necessary. For any patients in
whom we are considering induction therapy, they will not proceed
to systemic therapy without a biopsy.
In terms of the utility of PET, we prefer to obtain PET scans on
these patients, if possible, looking for distant metastases. This
might be more relevant in the setting of TC. Sometimes these pa-
tients come to us from the outside already having had a PET
scan. If not, we try to obtain one.
Dr Handy. Second, because TC fails distantly regardless of the
completeness of the resection, are you rethinking induction chemo-
therapy, and what agents are you using nowadays?
Dr Huang. In terms of systemic therapy, we have traditionally
been treating TCs with the same regimens with which we have
treated thymomas in the past. The most commonly used regimens
at our institution have been cisplatin, doxorubicin, and cyclophos-
phamide or cisplatin, and etoposide.1,2 We have been using thoseThe Journal of Thoracic andfor thymomas and TCs. However, recently, some of our oncologists
have started to approach TCs as a different disease. Because they
seem to be predominantly squamous in histology, we have been ap-
proaching some of these patients with a regimen, such as cisplatin
and docetaxel, more like non–small cell lung cancer.
Several reports now have shown that there is a high proportion of
thymic tumors that overexpress epidermal growth factor receptor,3
raising the possibility of using targeted therapies for these thymic
tumors, and this is an area of active investigation.
Dr Handy. Finally, in light of this report and your publication
last year of use of extended resection in stage IVA thymomas,
how is Sloan–Kettering presently caring for these patients with thy-
moma? Who is receiving chemotherapy and radiation therapy, and
what about reresection, because these are local recurrences? Nice
job on the presentation.
Dr Huang. In general, for the patients with early-stage dis-
ease that is smaller and well encapsulated, most will proceed
straight to surgical intervention. The more challenging patients
that we face are the patients with higher-stage, locally advanced
disease, which present to us with clinically stage III or IVA tu-
mors. These patients will typically need a biopsy to demonstrate
their pathology and then proceed to induction therapy with one
of the regimens that I mentioned before with the goal of treating
to maximum response, usually about 4 cycles of treatment. At
that point, they proceed to surgical resection if they are medi-
cally operable, where the goal is a total thymectomy with en-
bloc resection as necessary. In some cases this might lead to
extended resections, including extrapleural pneumonectomy, if
necessary, in cases of extensive confluent disease, as recently re-
ported by our group and others.4,5 After resection, every patient
with an incomplete resection will receive radiation therapy post-
operatively. Patients with stage III and IVA tumors will usually
receive mediastinal radiation after complete resections. For those
patients who have undergone extrapleural pneumonectomy, these
patients have received hemithoracic radiation to the chest cavity
akin to our approach to pleural mesothelioma.6
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